BioXcel: Patent Application OKd for Method of Treating Agitation in Alzheimer’s Disease

 Aligns with Company’s strategic focus on bringing to market BXCL501 for potential acute treatment of agitation for Alzheimer’s patients 

IGALMI™ market exclusivity further strengthened with receipt of issue notification for additional method of use patent (total of 8 U.S. patents, including 4 method of use patents) 

https://www.globenewswire.com/news-release/2024/02/05/2823402/0/en/BioXcel-Therapeutics-Announces-USPTO-s-Allowance-of-Patent-Application-for-Method-of-Treating-Agitation-in-Alzheimer-s-Disease-Using-Oromucosal-Formulations-of-Dexmedetomidine.html